{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:35:27Z","timestamp":1793918127526,"version":"4.8.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017668","name":"Anhui Provincial Key Research and Development Plan","doi-asserted-by":"publisher","award":["2022e07020018"],"award-info":[{"award-number":["2022e07020018"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","award":["2024AH051913"],"award-info":[{"award-number":["2024AH051913"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104011"],"award-info":[{"award-number":["82104011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118490","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:08:42Z","timestamp":1765843722000},"page":"118490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Emerging small-molecule AKR1C3 inhibitors development for cancer therapy: Progress from 2021 to 2025"],"prefix":"10.1016","volume":"304","author":[{"given":"Hao-Nan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Sen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Xue","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Tao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Dong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-4296","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118490_bib1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1124\/pharmrev.120.000122","article-title":"Aldo-keto reductases and cancer drug resistance","volume":"73","author":"Penning","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.118490_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and functional biology of aldo-keto reductase steroid-transforming enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2025.118490_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41388-022-02566-6","article-title":"Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer","volume":"42","author":"Yang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118490_bib4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41416-018-0014-0","article-title":"AKR1C enzymes sustain therapy resistance in paediatric T-ALL","volume":"118","author":"Bortolozzi","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118490_bib5","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41388-022-02379-7","article-title":"AKR1C3 regulated by NRF2\/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma","volume":"41","author":"Pan","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118490_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.freeradbiomed.2025.02.005","article-title":"Skin sensitizers enhance superoxide formation by polycyclic aromatic hydrocarbons via the aldo-keto reductase pathway","volume":"230","author":"Eberle","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118490_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24031873","article-title":"Germline mutations in steroid metabolizing enzymes: a focus on steroid transforming aldo-keto reductases","volume":"24","author":"Detlefsen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118490_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118490_bib9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/CM9.0000000000001379","article-title":"Roles of AKR1C3 in malignancy","volume":"134","author":"Xiao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ejmech.2025.118490_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40268-023-00427-5","article-title":"Hepatotoxicity of AKR1C3 inhibitor BAY1128688: findings from an early terminated phase IIa trial for the treatment of endometriosis","volume":"23","author":"Hilpert","year":"2023","journal-title":"Drugs R&D"},{"key":"10.1016\/j.ejmech.2025.118490_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10637-014-0101-x","article-title":"Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I\/II study","volume":"32","author":"Loriot","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2025.118490_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-011-1671-3","article-title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","volume":"68","author":"Abou-Alfa","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118490_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0009-2797(02)00193-X","article-title":"The aldo-keto reductase superfamily homepage","volume":"143\u2013144","author":"Hyndman","year":"2003","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib15","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","article-title":"Overview of AKR1C3: inhibitor achievements and disease insights","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib16","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1074\/jbc.M606784200","article-title":"Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase","volume":"282","author":"Qiu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib17","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1021\/bi036046x","article-title":"Crystal structure of human prostaglandin F synthase (AKR1C3)","volume":"43","author":"Komoto","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118490_bib18","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1021\/bi9723055","article-title":"Mutagenesis of 3 alpha-hydroxysteroid dehydrogenase reveals a \"push-pull\" mechanism for proton transfer in aldo-keto reductases","volume":"37","author":"Schlegel","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118490_bib19","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/0008-5472.CAN-03-2847","article-title":"Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin","volume":"64","author":"Lovering","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib20","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/me.2004-0032","article-title":"Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues","volume":"18","author":"Qiu","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118490_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsbmb.2010.11.004","article-title":"Inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights","volume":"125","author":"Byrns","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118490_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118490_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41419-025-07773-z","article-title":"AKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5","volume":"16","author":"Ju","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118490_bib24","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/pros.23874","article-title":"Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion","volume":"79","author":"Kaipainen","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2025.118490_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fphar.2017.00119","article-title":"Aldo-keto reductase AKR1C1-AKR1C4: functions, regulation, and intervention for anti-cancer therapy","volume":"8","author":"Zeng","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118490_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.mce.2005.12.009","article-title":"Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors","volume":"248","author":"Penning","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118490_bib27","doi-asserted-by":"crossref","first-page":"20865","DOI":"10.1074\/jbc.M115.662155","article-title":"The steroidogenic enzyme AKR1C3 regulates stability of the ubiquitin ligase Siah2 in prostate cancer cells","volume":"290","author":"Fan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib28","doi-asserted-by":"crossref","first-page":"472.e411","DOI":"10.1016\/j.urolonc.2018.07.005","article-title":"AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling","volume":"36","author":"Wang","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118490_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","article-title":"Epithelial-to-mesenchymal transition in cancer: complexity and opportunities","volume":"12","author":"Zhang","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2025.118490_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118490_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2008.04.004","article-title":"AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K\/Akt proliferative signaling pathway in human prostate cancer cells","volume":"289","author":"Wang","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118490_bib32","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2119\/molmed.2012.00296","article-title":"Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer","volume":"18","author":"Hamid","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118490_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jsbmb.2011.12.012","article-title":"Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5\u03b1-reductase inhibitor finasteride","volume":"130","author":"Byrns","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118490_bib34","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.ejmech.2025.118490_bib35","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-17-1023","article-title":"AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells","volume":"17","author":"Verma","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118490_bib36","first-page":"14","article-title":"The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer","author":"Zheng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118490_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118490_bib38","doi-asserted-by":"crossref","first-page":"312re310","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118490_bib39","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.2174\/092986711795933713","article-title":"Inhibitors of aldo-keto reductases AKR1C1-AKR1C4","volume":"18","author":"Bro\u017ei\u010d","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118490_bib41","first-page":"4378","article-title":"Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejmech.2025.118490_bib42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10549-014-2942-6","article-title":"Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes","volume":"145","author":"McNamara","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2025.118490_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.exphem.2009.04.002","article-title":"Acute myelogenous leukemia","volume":"37","author":"Shipley","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2025.118490_bib44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2014.04.027","article-title":"Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3","volume":"278","author":"Hofman","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118490_bib45","first-page":"505","article-title":"The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs","volume":"63","author":"Desmond","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib46","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-20-2480","article-title":"A positive feedback loop of AKR1C3-Mediated activation of NF-\u03baB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054513","article-title":"Establishing a proteomics-based signature of AKR1C3-Related genes for predicting the prognosis of prostate cancer","volume":"24","author":"Cui","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118490_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/EJE-20-1077","article-title":"Peripheral blood mononuclear cells preferentially activate 11-oxygenated androgens","volume":"184","author":"Schiffer","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118490_bib49","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.7150\/jca.94228","article-title":"Defining the biological functions and clinical significance of AKR1C3 in gastric carcinogenesis through multiomics functional analysis and immune infiltration analysis","volume":"15","author":"Shao","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118490_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.32604\/or.2023.030975","article-title":"Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2\u03b1","volume":"32","author":"Jeng","year":"2023","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib51","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.7150\/thno.74974","article-title":"AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.118490_bib52","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mc.23527","article-title":"AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP\/SLC7A11 signaling pathway","volume":"62","author":"Chen","year":"2023","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ejmech.2025.118490_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.mce.2005.10.009","article-title":"AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer","volume":"248","author":"Rizner","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118490_bib54","first-page":"608","article-title":"Suppressed expression of type 2 3alpha\/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma","volume":"3","author":"Zakharov","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.ejmech.2025.118490_bib55","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/carcin\/bgh240","article-title":"Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions","volume":"25","author":"Lan","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2025.118490_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102027","article-title":"AKR1C3 promotes progression and mediates therapeutic resistance by inducing epithelial-mesenchymal transition and angiogenesis in small cell lung cancer","volume":"47","author":"Liu","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2025.118490_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108839","article-title":"Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells","volume":"314","author":"Matsunaga","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cbi.2012.09.024","article-title":"Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers","volume":"202","author":"Matsunaga","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib59","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3892\/ijmm.2013.1268","article-title":"15-Deoxy-\u0394(12,14)-prostaglandin J(2) induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer cell lines","volume":"31","author":"Li","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118490_bib60","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ygyno.2013.11.032","article-title":"Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix","volume":"132","author":"Wu","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118490_bib61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1139\/bcb-2015-0096","article-title":"Transcript level of AKR1C3 is down-regulated in gastric cancer","volume":"94","author":"Frycz","year":"2016","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.ejmech.2025.118490_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82039-w","article-title":"AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK\/p-NF-\u03baB signaling pathways","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118490_bib63","doi-asserted-by":"crossref","first-page":"899","DOI":"10.26599\/1671-5411.2024.09.001","article-title":"Aldo-keto reductase 1C3 reduces myocardial cell damage after acute myocardial infarction by activating the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-antioxidant response element pathway to inhibit ferroptosis","volume":"21","author":"Miao","year":"2024","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.ejmech.2025.118490_bib64","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cbin.11789","article-title":"ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3","volume":"46","author":"Li","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejmech.2025.118490_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043965","article-title":"Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3","volume":"7","author":"Flanagan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118490_bib66","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","volume":"75","author":"Byrns","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118490_bib67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1039\/D4MD00297K","article-title":"Synthesis and biological evaluation of novel D-ring fused steroidal N(2)-substituted-1,2,3-triazoles","volume":"16","author":"Tenjovi\u0107","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cbi.2014.12.015","article-title":"Screening baccharin analogs as selective inhibitors against type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3)","volume":"234","author":"Zang","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib69","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1021\/acs.jmedchem.3c00213","article-title":"Development of biaryl-containing aldo-keto reductase 1C3 (AKR1C3) inhibitors for reversing AKR1C3-Mediated drug resistance in cancer treatment","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000519","article-title":"Design, synthesis and cytotoxicity evaluation of novel indole derivatives containing benzoic acid group as potential AKR1C3 inhibitors","volume":"17","author":"Sun","year":"2020","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2025.118490_bib71","doi-asserted-by":"crossref","first-page":"9967","DOI":"10.1021\/bi000789q","article-title":"The sorbinil trap: a predicted dead-end complex confirms the mechanism of aldose reductase inhibition","volume":"39","author":"Bohren","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118490_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114366","article-title":"New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold","volume":"237","author":"Pippione","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib73","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ejmech.2018.03.040","article-title":"Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid","volume":"150","author":"Pippione","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116193","article-title":"Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer","volume":"268","author":"Pippione","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib75","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1021\/ci4001597","article-title":"Characterization of biaryl torsional energetics and its treatment in OPLS all-atom force fields","volume":"53","author":"Dahlgren","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118490_bib76","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1039\/D2MD00387B","article-title":"X-ray structure of human aldo-keto reductase 1C3 in complex with a bile acid fused tetrazole inhibitor: experimental validation, molecular docking and structural analysis","volume":"14","author":"Marinovi\u0107","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116179","article-title":"Anticancer mechanism of coumarin-based derivatives","volume":"267","author":"Yadav","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib78","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.neuro.2012.08.015","article-title":"Inducible protection of human astrocytoma 1321N1 cells against hydrogen peroxide and aldehyde toxicity by 7-hydroxycoumarin is associated with the upregulation of aldo-keto reductases","volume":"33","author":"Li","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejmech.2025.118490_bib79","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acsmedchemlett.4c00150","article-title":"AI based discovery of a new AKR1C3 inhibitor for anticancer applications","volume":"15","author":"Pippione","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118490_bib80","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","article-title":"Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-Cell acute lymphoblastic leukemia","volume":"62","author":"Verma","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib81","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1021\/acs.jmedchem.3c00732","article-title":"Aldo-keto reductase 1C3 inhibitor prodrug improves pharmacokinetic profile and demonstrates in vivo efficacy in a prostate cancer xenograft model","volume":"66","author":"Maddeboina","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115013","article-title":"Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer","volume":"247","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib83","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib84","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1021\/acs.jmedchem.5c00050","article-title":"Discovery and optimization of a covalent AKR1C3 inhibitor","volume":"68","author":"Grams","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib85","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41589-019-0404-5","article-title":"Global targeting of functional tyrosines using sulfur-triazole exchange chemistry","volume":"16","author":"Hahm","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118490_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202400382","article-title":"Imidazoles are tunable nucleofuges for developing tyrosine-reactive electrophiles","volume":"25","author":"Justin Grams","year":"2024","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2025.118490_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400081","article-title":"Coumarin-based aldo-keto reductase family 1C (AKR1C) 2 and 3 inhibitors","volume":"19","author":"Jonnalagadda","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118490_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12020099","article-title":"Analogues of natural chalcones as efficient inhibitors of AKR1C3","volume":"12","author":"M\u00f6ller","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.ejmech.2025.118490_bib89","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1021\/acsmedchemlett.2c00175","article-title":"Discovery of novel aldo-keto reductase 1C3 inhibitors as chemotherapeutic potentiators for cancer drug resistance","volume":"13","author":"He","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118490_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110654","article-title":"Inhibition of AKR1Cs by liquiritigenin and the structural basis","volume":"385","author":"Liu","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082092","article-title":"Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer","volume":"12","author":"Kafka","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118490_bib92","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17460441.2020.1732920","article-title":"Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor","volume":"15","author":"Sadar","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118490_bib93","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4155\/fmc-2024-0039","article-title":"Synthesis, in vitro and in silico anticancer evaluation of novel pyridin-2-yl estra-1,3,5(10)-triene derivatives","volume":"16","author":"Stevanovi\u0107","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib94","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/0008-5472.CAN-24-0440","article-title":"LX1 dual targets AR variants and AKR1C3 in advanced prostate cancer therapy","volume":"84","author":"Ning","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib95","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118490_bib96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42004-024-01177-4","article-title":"Discovery of an aldo-keto reductase 1C3 (AKR1C3) degrader","volume":"7","author":"Carmona","year":"2024","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib97","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bcp.2007.06.014","article-title":"Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia","volume":"74","author":"Guise","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118490_bib98","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","article-title":"The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3","volume":"70","author":"Guise","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib99","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3324\/haematol.2014.118455","article-title":"Phase I\/II study of the hypoxia-activated prodrug PR104 in refractory\/relapsed acute myeloid leukemia and acute lymphoblastic leukemia","volume":"100","author":"Konopleva","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118490_bib100","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.111.180703","article-title":"Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy","volume":"337","author":"Gu","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118490_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121231","article-title":"Restoring tumour selectivity of the bioreductive prodrug PR-104 by developing an analogue resistant to aerobic metabolism by human aldo-keto reductase 1C3","volume":"14","author":"Abbattista","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2025.118490_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020185","article-title":"Interrogation of the structure-activity relationship of a lipophilic nitroaromatic prodrug series designed for cancer gene therapy applications","volume":"15","author":"Ashoorzadeh","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2025.118490_bib103","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/acsmedchemlett.3c00321","article-title":"Design and biological evaluation of piperazine-bearing nitrobenzamide Hypoxia\/GDEPT prodrugs: the discovery of CP-506","volume":"14","author":"Ashoorzadeh","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118490_bib104","first-page":"3645","article-title":"A novel selective AKR1C3-activated prodrug AST-3424\/OBI-3424 exhibits broad anti-tumor activity","volume":"11","author":"Meng","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-024-01180-x","article-title":"The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia","volume":"14","author":"Toscan","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmech.2025.118490_bib106","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a novel AKR1C3-Activated prodrug, exhibits potent efficacy against preclinical models of T-ALL","volume":"25","author":"Evans","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib107","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2014-12-618900","article-title":"AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia","volume":"126","author":"Moradi Manesh","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118490_bib108","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","article-title":"Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib109","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbi.2008.10.015","article-title":"AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids","volume":"178","author":"Skarydov\u00e1","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118490_bib111","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cbi.2014.11.005","article-title":"Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3","volume":"234","author":"Traven","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118490_bib112","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1039\/D1MD00068C","article-title":"Recent advances in the development of covalent inhibitors","volume":"12","author":"Kim","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib113","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-024-47120-y","article-title":"De novo generation of multi-target compounds using deep generative chemistry","volume":"15","author":"Munson","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118490_bib114","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118490_bib115","article-title":"Multi-target drugs: the trend of drug research and development","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118490_bib116","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejmech.2025.118490_bib117","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104376","article-title":"Protac 2.0: expanding the frontiers of targeted protein degradation","volume":"30","author":"Cornu","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118490_bib119","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10428194.2020.1728746","article-title":"An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2025.118490_bib120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jphs.2023.03.004","article-title":"A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma","volume":"152","author":"Xun","year":"2023","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118490_bib121","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41420-025-02410-2","article-title":"Functions and mechanisms of non-histone post-translational modifications in cancer progression","volume":"11","author":"Li","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.118490_bib122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2020.01.011","article-title":"Targeting cancer cells with nanotherapeutics and nanodiagnostics: current status and future perspectives","volume":"69","author":"Ali","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118490_bib123","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2017.07.023","article-title":"MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers","volume":"126","author":"Singh","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118490_bib124","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-022-01561-5","article-title":"Reprogramming the tumor microenvironment by genome editing for precision cancer therapy","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118490_bib125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:18:38Z","timestamp":1773929918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":125,"alternative-id":["S0223523425012553"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118490","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging small-molecule AKR1C3 inhibitors development for cancer therapy: Progress from 2021 to 2025","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118490"}}